MacroGenics
53
3
8
24
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.2%
16 terminated/withdrawn out of 53 trials
60.0%
-26.6% vs industry average
4%
2 trials in Phase 3/4
100%
24 of 24 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (53)
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Role: collaborator
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Role: lead
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Role: collaborator
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
Role: collaborator
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Role: collaborator
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Role: lead
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Role: lead
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
Role: collaborator
A Study of MGC028 in Participants With Advanced Solid Tumors
Role: lead
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
Role: collaborator
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Role: lead
A Study of MGC026 in Participants With Advanced Solid Tumors
Role: lead
MARGetuximab Or Trastuzumab (MARGOT)
Role: collaborator
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Role: lead
Post-transplant Flotetuzumab for AML
Role: collaborator
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Role: lead
MGC018 With or Without MGA012 in Advanced Solid Tumors
Role: lead
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
Role: collaborator
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Role: lead
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Role: lead